AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9233529 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 on day 1 and oral etoposide 100 mg daily on days 1 to 5 (schedule A)
Number of subjects: 49
Study 9233529 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 160 mg/m2 on day 5 (schedule B)
Number of subjects: 49
Study 9233529 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 on day 1 with oral etoposide 100 mg daily on days 1 to 5 (schedule A)
Number of subjects: 49
Study 1345132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin (50 units/kg IV immediately after antivenom, followed by continuous infusion of 10 units/kg/hour for 24 hours)
Number of subjects: 20
Study 1345132 — intervention group
Group type: COMPARATOR
Intervention: Antivenom alone
Number of subjects: 20
Study 1345132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin
Number of subjects: 20
Study 3549872 — intervention group
Group type: COMPARATOR
Intervention: Piracetam 2 X 3 g
Number of subjects: 24
Study 3549872 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 2 X 12 g
Number of subjects: 24
Study 3549872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30329199 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drug (0.5 mg tyrothricin, 1.0 mg benzalkonium chloride, and 1.5 mg benzocaine)
Number of subjects: 321
Study 30329199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 27782838 — intervention group
Group type: EXPERIMENTAL
Intervention: High parental involvement
Number of subjects: 347
Study 27782838 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium parental involvement
Number of subjects: 347
Study 27782838 — intervention group
Group type: COMPARATOR
Intervention: Low/no parental involvement
Number of subjects: 347
Study 25042199 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (11 mg/kg intravenous infusion every 3 weeks)
Number of subjects: 79
Study 25042199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 25042199 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab
Number of subjects: 79
Study 22397837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol chocolate containing maltitol (266 mg)
Number of subjects: 15
Study 22397837 — intervention group
Group type: COMPARATOR
Intervention: High-flavanol chocolate with sucrose (251 mg)
Number of subjects: 15
Study 22397837 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol chocolate with sucrose (48 mg)
Number of subjects: 15
Study 19905846 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded rapid maxillary expander (RME) followed by a removable maintenance plate and a transpalatal arch
Number of subjects: 500
Study 19905846 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 500
Study 18245199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing lower rate 70 ppm and prevention and ATP therapies ON
Number of subjects: 38
Study 18245199 — intervention group
Group type: COMPARATOR
Intervention: Atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF
Number of subjects: 38
Study 18245199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing lower rate 70 ppm and prevention and ATP therapies ON with septal lead placement
Number of subjects: 38
Study 18245199 — intervention group
Group type: COMPARATOR
Intervention: Atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF with septal lead placement
Number of subjects: 38
Study 16193675 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A injections (20 units in one single injection)
Number of subjects: 36
Study 16193675 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A injections
Number of subjects: 36
Study 12956915 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of two per cent lignocaine and adrenaline 1:200000 with 1500 IU hyaluronidase
Number of subjects: 40
Study 12956915 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of two per cent lignocaine and adrenaline 1:200000
Number of subjects: 40
Study 10384194 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicaval technique
Number of subjects: 201
Study 10384194 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 201
Study 8698355 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MIU interferon alpha‐2a
Number of subjects: 250
Study 8698355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MIU interferon alpha‐2a
Number of subjects: 250
Study 8698355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 2070654 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil and pyruvic acid
Number of subjects: 12
Study 2070654 — intervention group
Group type: COMPARATOR
Intervention: pyruvic acid alone
Number of subjects: 12
Study 2070654 — intervention group
Group type: COMPARATOR
Intervention: 5 percent 5‐fluorouracil cream
Number of subjects: 12
Study 29536456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternal Talon
Number of subjects: 338
Study 29536456 — intervention group
Group type: COMPARATOR
Intervention: Wire cerclage
Number of subjects: 338
Study 27569737 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of intravenous ibuprofen injection (0.2g, 0.4g, 0.8g) administered as a 30-minute IV infusion.
Number of subjects: 12
Study 27569737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of intravenous ibuprofen (0.4g every 6 hours for 9 doses).
Number of subjects: 12
Study 27569737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerability assessment of intravenous ibuprofen.
Number of subjects: 12
Study 24576858 — intervention group
Group type: COMPARATOR
Intervention: Control trial (CON)
Number of subjects: 17
Study 24576858 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of fast‐acting β2‐agonist (BD)
Number of subjects: 17
Study 24576858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham to the hyperpnea (SHAM)
Number of subjects: 17
Study 24576858 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperpnea challenge (BC)
Number of subjects: 17
Study 22958874 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg dextromethorphan
Number of subjects: 0
Study 22958874 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diphenhydramine)
Number of subjects: 0
Study 20189608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion therapy
Number of subjects: 65
Study 20189608 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 65
Study 18514865 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal oral pain medication protocol including preemptive oral analgesics, epidural anesthesia, pericapsular analgesic injection, and postoperative analgesia without parenteral opioids
Number of subjects: 70
Study 18514865 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal oral pain medication protocol
Number of subjects: 70
Study 16230877 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin extended-release/lovastatin 1000/40 mg
Number of subjects: 0
Study 16230877 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin 10 mg
Number of subjects: 0
Study 16230877 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 10 mg and 20 mg
Number of subjects: 0
Study 12967694 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medications
Number of subjects: 2535
Study 10919590 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 10919590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0
Study 10919590 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 8706296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous beta-endorphin 5 mg/50 ml
Number of subjects: 6
Study 8706296 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 6
Study 1796228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 58
Study 1796228 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 3 mg/kg
Number of subjects: 58
Study 1796228 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 6 mg/kg
Number of subjects: 58
Study 1796228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 1796228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg and DEC 3 mg/kg (twice a year)
Number of subjects: 58
Study 1796228 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilaricidal drugs
Number of subjects: 58
Study 6849786 — intervention group
Group type: EXPERIMENTAL
Intervention: Solpadeine (paracetamol with codeine and caffeine)
Number of subjects: 4
Study 6849786 — intervention group
Group type: COMPARATOR
Intervention: Panadol (paracetamol alone)
Number of subjects: 4
Study 6849786 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramax (paracetamol with metoclopramide)
Number of subjects: 4
Study 31251709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis group (HG)
Number of subjects: 22
Study 31251709 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study 28621820 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT)
Number of subjects: 132
Study 28621820 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 132
Study 26660768 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Improvement Project for Teens (HIPTeens)
Number of subjects: 0
Study 25261884 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW weight loss intervention
Number of subjects: 136
Study 25261884 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW weight loss intervention (responder sites)
Number of subjects: 136
Study 25261884 — intervention group
Group type: COMPARATOR
Intervention: Control condition (treatment as usual)
Number of subjects: 136
Study 23101771 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS with its tip inserted into the vallecula for indirect elevation of the epiglottis (Group AWS-I; n = 30)
Number of subjects: 90
Study 23101771 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS with its tip positioned posterior to the epiglottis for direct elevation of the epiglottis (Group AWS-D; n = 30)
Number of subjects: 90
Study 23101771 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group Mac; n = 30)
Number of subjects: 90
Study 19767268 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐s TV ad simulation
Number of subjects: 426
Study 19767268 — intervention group
Group type: EXPERIMENTAL
Intervention: Billboard simulation
Number of subjects: 426
Study 19767268 — intervention group
Group type: COMPARATOR
Intervention: No-information condition
Number of subjects: 426
Study 17638634 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl suppository
Number of subjects: 20
Study 17638634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15614010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (NSAID)
Number of subjects: 17
Study 15614010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12173729 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 25 mg t.i.d.
Number of subjects: 468
Study 12173729 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg t.i.d.
Number of subjects: 468
Study 12173729 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg t.i.d.
Number of subjects: 468
Study 12173729 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 200 mg t.i.d.
Number of subjects: 468
Study 12173729 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 468
Study 9452226 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-drugs-in-1-day (8-in-1) chemotherapy followed by radiotherapy
Number of subjects: 18
Study 9452226 — intervention group
Group type: COMPARATOR
Intervention: Craniospinal radiotherapy
Number of subjects: 18
Study 9452226 — intervention group
Group type: COMPARATOR
Intervention: Spinal radiotherapy
Number of subjects: 18
Study 9452226 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 cycles of chemotherapy
Number of subjects: 18
Study 9452226 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 18
Study 9452226 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse at primary site
Number of subjects: 18
Study 7884950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8
Number of subjects: 3404
Study 7884950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3404
Study 7884950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant treatment
Number of subjects: 3404
Study 2203215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 64
Study 2203215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 192808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenine arabinoside (ara‐A)
Number of subjects: 13
Study 192808 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 13
Study 30739540 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) plus routine COPD medical treatment
Number of subjects: 42
Study 30739540 — intervention group
Group type: COMPARATOR
Intervention: Routine COPD medical treatment
Number of subjects: 42
Study 30928442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dilatation (pre-BAV)
Number of subjects: 171
Study 30928442 — intervention group
Group type: COMPARATOR
Intervention: No pre-dilatation (no-BAV)
Number of subjects: 171
Study 30928442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study 29197413 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of NOAC therapy (≤ 4 days after stroke onset)
Number of subjects: 3000
Study 29197413 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of NOAC therapy (≥ 5-10 days after stroke onset)
Number of subjects: 3000
Study 25936237 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-shaped intrauterine balloon
Number of subjects: 201
Study 25936237 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine contraceptive device (IUD)
Number of subjects: 201
Study 23369879 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg amlodipine/80mg atorvastatin (test product)
Number of subjects: 29
Study 23369879 — intervention group
Group type: COMPARATOR
Intervention: CADUET(®) (reference product)
Number of subjects: 29
Study 21900198 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (CHOP with rituximab)
Number of subjects: 512
Study 21900198 — intervention group
Group type: COMPARATOR
Intervention: CHOP (without rituximab)
Number of subjects: 512
Study 19473629 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ARB (losartan 200 mg/day)
Number of subjects: 207
Study 19473629 — intervention group
Group type: COMPARATOR
Intervention: Normal dose ARB (losartan 100 mg/day)
Number of subjects: 207
Study 19473629 — intervention group
Group type: COMPARATOR
Intervention: Normal dose ACEI (20 mg/day)
Number of subjects: 207
Study 19473629 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ACEI (10 mg/day)
Number of subjects: 207
Study 16115616 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's knowledge of number words beyond those they have mastered
Number of subjects: 0
Study 16115616 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's productive symbolic system for representing number
Number of subjects: 0
Study 15558520 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodialysis (CVVHD)
Number of subjects: 80
Study 15558520 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 80
Study 11783049 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9519234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 2 mg daily via metered-dose inhaler and Volumatic
Number of subjects: 30
Study 9519234 — intervention group
Group type: COMPARATOR
Intervention: Nebulized budesonide (nBUD)
Number of subjects: 30
Study 8592675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (NEF) infused into the proximal intestine (400 mg over 5 hours)
Number of subjects: 10
Study 8592675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (NEF) infused into the distal intestine (400 mg over 5 hours)
Number of subjects: 10
Study 8592675 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone (NEF) administered orally (10 divided doses over 4.5 hours)
Number of subjects: 10
Study 2528028 — intervention group
Group type: EXPERIMENTAL
Intervention: abdominal crunch (AC) weight machine
Number of subjects: 45
Study 2528028 — intervention group
Group type: EXPERIMENTAL
Intervention: seated incline (SI) weight machine
Number of subjects: 45
Study 2528028 — intervention group
Group type: EXPERIMENTAL
Intervention: incline sit-up (ISU) exercise
Number of subjects: 45
Study 793781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nethaprin Dospan (active drug)
Number of subjects: 48
Study 793781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31155953 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract (BSE) 200 µmol daily
Number of subjects: 98
Study 31155953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 30385101 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Medicine (NM) workshop
Number of subjects: 103
Study 30385101 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 103
Study 28777758 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2mg (Bydureon) administered via once-weekly subcutaneous injections for 48 weeks
Number of subjects: 0
Study 28777758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24585506 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg orally daily
Number of subjects: 37
Study 24585506 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 22211733 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal plus 3.5 g l-Lys/kg diet (T2)
Number of subjects: 20
Study 22211733 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal plus 1.5 g l-Leu/kg diet (T3)
Number of subjects: 20
Study 22211733 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal plus 3.5 g l-Lys plus 1.5 g l-Leu/kg diet (T4)
Number of subjects: 20
Study 22211733 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (T1)
Number of subjects: 20
Study 22151477 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin/mineral supplement
Number of subjects: 141
Study 22151477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 19957624 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine from lot 1
Number of subjects: 566
Study 19957624 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine from lot 2
Number of subjects: 566
Study 19957624 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine from lot 3
Number of subjects: 566
Study 19957624 — intervention group
Group type: COMPARATOR
Intervention: Licensed control vaccine
Number of subjects: 566
Study 16362241 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal perceptions of neighborhood characteristics (collective efficacy, barriers to services, negative neighbor affects, probability of child status attainment success, overall neighborhood rating)
Number of subjects: 576
Study 16362241 — intervention group
Group type: EXPERIMENTAL
Intervention: Family income
Number of subjects: 576
Study 15488111 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient interventions
Number of subjects: 563
Study 11129341 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFRSF6 GG-genotype in APOE4 carriers
Number of subjects: 675
Study 11129341 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFRSF6 GG-genotype in EOAD cases
Number of subjects: 675
Study 11129341 — intervention group
Group type: COMPARATOR
Intervention: TNFRSF6 GG-genotype in initial study
Number of subjects: 675
Study 11129341 — intervention group
Group type: COMPARATOR
Intervention: TNFRSF6 GG-genotype overall association
Number of subjects: 675
Study 8839875 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCT
Number of subjects: 40
Study 8839875 — intervention group
Group type: COMPARATOR
Intervention: BMT
Number of subjects: 40
Study 1771375 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat (2.26% fluoride), applied every 6 months, n = 185
Number of subjects: 495
Study 1771375 — intervention group
Group type: COMPARATOR
Intervention: Carex (1.8% fluoride), applied every 6 months, n = 165
Number of subjects: 495
Study 6943174 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental method (guided systematic approach with detailed checklists and exhaustive faculty feedback)
Number of subjects: 88
Study 6943174 — intervention group
Group type: COMPARATOR
Intervention: Control method (traditional teaching method used at the University of North Carolina School of Dentistry)
Number of subjects: 88
Study 6943174 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental method
Number of subjects: 88
Study 31112203 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified α‐1,3‐glucan solution
Number of subjects: 0
Study 31112203 — intervention group
Group type: EXPERIMENTAL
Intervention: Random silencing of hydrogen bonding donor sites
Number of subjects: 0
Study 31112203 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific silencing of the hydrogen-bonding site on the C6 carbon
Number of subjects: 0
Study 31112203 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hydrogen bond strengths
Number of subjects: 0
Study 28716797 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular low-dose extended-release morphine
Number of subjects: 171
Study 28716797 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward titration of morphine after initial benefit
Number of subjects: 171
Study 28716797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 26036212 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen at 0.625 mg/d (n=5279)
Number of subjects: 10739